KYORIN Pharmaceutical Co., Ltd. (TYO:4569)
Japan
· Delayed Price · Currency is JPY 1,660.00
-5.00 (-0.30%)
At close: Mar 6, 2026
KYORIN Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 133,257 | 130,087 | 119,532 | 113,270 | 105,534 | 102,904 | Upgrade
|
| Revenue Growth (YoY) | 9.63% | 8.83% | 5.53% | 7.33% | 2.56% | -6.44% | Upgrade
|
| Cost of Revenue | 72,860 | 70,551 | 68,124 | 63,102 | 56,093 | 51,276 | Upgrade
|
| Gross Profit | 60,397 | 59,536 | 51,408 | 50,168 | 49,441 | 51,628 | Upgrade
|
| Selling, General & Admin | 35,820 | 36,453 | 37,375 | 34,140 | 35,536 | 36,138 | Upgrade
|
| Research & Development | 10,514 | 10,514 | 8,019 | 10,903 | 8,897 | 9,703 | Upgrade
|
| Operating Expenses | 46,396 | 46,989 | 45,402 | 45,047 | 44,437 | 45,853 | Upgrade
|
| Operating Income | 14,001 | 12,547 | 6,006 | 5,121 | 5,004 | 5,775 | Upgrade
|
| Interest Expense | -254 | -173 | -66 | -66 | -66 | -68 | Upgrade
|
| Interest & Investment Income | 508 | 497 | 500 | 465 | 410 | 420 | Upgrade
|
| Earnings From Equity Investments | 40 | 38 | -12 | - | 25 | 49 | Upgrade
|
| Currency Exchange Gain (Loss) | 208 | 165 | 59 | 78 | 98 | 129 | Upgrade
|
| Other Non Operating Income (Expenses) | 58 | 144 | 114 | 228 | 97 | 143 | Upgrade
|
| EBT Excluding Unusual Items | 14,561 | 13,218 | 6,601 | 5,826 | 5,568 | 6,448 | Upgrade
|
| Gain (Loss) on Sale of Investments | 64 | -305 | 1,403 | 70 | -320 | 488 | Upgrade
|
| Gain (Loss) on Sale of Assets | -104 | -127 | -90 | -15 | -32 | 342 | Upgrade
|
| Asset Writedown | - | - | - | -257 | - | - | Upgrade
|
| Other Unusual Items | 203 | -16 | -896 | 1,281 | - | 1,074 | Upgrade
|
| Pretax Income | 14,724 | 12,770 | 7,018 | 6,905 | 5,216 | 8,352 | Upgrade
|
| Income Tax Expense | 3,958 | 3,684 | 1,696 | 2,182 | 1,284 | 2,222 | Upgrade
|
| Net Income | 10,766 | 9,086 | 5,322 | 4,723 | 3,932 | 6,130 | Upgrade
|
| Net Income to Common | 10,766 | 9,086 | 5,322 | 4,723 | 3,932 | 6,130 | Upgrade
|
| Net Income Growth | 179.85% | 70.73% | 12.68% | 20.12% | -35.86% | -0.31% | Upgrade
|
| Shares Outstanding (Basic) | 57 | 57 | 57 | 57 | 57 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 57 | 57 | 57 | 57 | 57 | Upgrade
|
| Shares Change (YoY) | -0.00% | 0.10% | 0.15% | 0.00% | 0.01% | 0.02% | Upgrade
|
| EPS (Basic) | 187.40 | 158.16 | 92.73 | 82.42 | 68.62 | 106.99 | Upgrade
|
| EPS (Diluted) | 187.40 | 158.16 | 92.73 | 82.42 | 68.62 | 106.99 | Upgrade
|
| EPS Growth | 179.86% | 70.55% | 12.51% | 20.11% | -35.86% | -0.33% | Upgrade
|
| Free Cash Flow | - | -2,191 | -4,229 | -4,322 | 3,902 | 1,122 | Upgrade
|
| Free Cash Flow Per Share | - | -38.14 | -73.69 | -75.42 | 68.09 | 19.58 | Upgrade
|
| Dividend Per Share | 32.000 | 52.000 | 52.000 | 52.000 | 52.000 | 75.000 | Upgrade
|
| Dividend Growth | -38.46% | - | - | - | -30.67% | - | Upgrade
|
| Gross Margin | 45.32% | 45.77% | 43.01% | 44.29% | 46.85% | 50.17% | Upgrade
|
| Operating Margin | 10.51% | 9.64% | 5.03% | 4.52% | 4.74% | 5.61% | Upgrade
|
| Profit Margin | 8.08% | 6.98% | 4.45% | 4.17% | 3.73% | 5.96% | Upgrade
|
| Free Cash Flow Margin | - | -1.68% | -3.54% | -3.82% | 3.70% | 1.09% | Upgrade
|
| EBITDA | 18,839 | 17,150 | 10,296 | 8,961 | 8,718 | 9,339 | Upgrade
|
| EBITDA Margin | 14.14% | 13.18% | 8.61% | 7.91% | 8.26% | 9.07% | Upgrade
|
| D&A For EBITDA | 4,838 | 4,603 | 4,290 | 3,840 | 3,714 | 3,564 | Upgrade
|
| EBIT | 14,001 | 12,547 | 6,006 | 5,121 | 5,004 | 5,775 | Upgrade
|
| EBIT Margin | 10.51% | 9.64% | 5.03% | 4.52% | 4.74% | 5.61% | Upgrade
|
| Effective Tax Rate | 26.88% | 28.85% | 24.17% | 31.60% | 24.62% | 26.60% | Upgrade
|
| Advertising Expenses | - | 4,589 | 5,593 | 4,714 | 4,731 | 5,784 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.